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Ovariectomy enhances renal cortical expression and function
of cyclooxygenase-2.
Background. Cyclooxygenase-2 (COX-2) inhibitors are used
as analgesics in postmenopausal women, who develop edema
and require a salt-restricted diet. This study was performed
to determine the renal expression of COX-2 and on COX-2–
dependent regulation of renal blood flow (RBF) in ovariec-
tomized rats.
Methods. Sprague-Dawley rats were divided into 4 groups:
sham-operated rats fed a normal-salt diet (Sh+NS) or a low-salt
diet (Sh+LS), and bilaterally ovariectomized rats fed a normal-
salt diet (Ox+NS) or a low-salt diet (Ox+LS) (N = 6 in each
group). Estrogen replacement therapy was performed on other
ovariectomized rats. A renal clearance study was performed in
anesthetized animals.
Results. Ovariectomy increased renal cortical COX-2 expres-
sion independently of dietary salt intake (Sh+NS <Ox+N;
Sh+LS <Ox+LS). Inhibition of COX-2 by NS398 reduced the
urinary excretion of 6-keto-prostaglandin F1a in all 4 groups,
although the reduction was greater in the Ox+LS group than
in the Ox+NS and Sh+LS groups, which in turn had a greater
reduction than the Sh+NS group. RBF significantly decreased
in every group except the Sh+NS group, but no effect on blood
pressure, inulin clearance, or urinary sodium excretion was seen.
The decrease in RBF was significantly greater in the Ox+LS
group than in the Sh+LS and Ox+NS group. The decrease
in RBF was dependent on cortical RBF in the Sh+LS and
Ox+NS groups, and on both cortical and medullary RBF in
the Ox+LS group. Estrogen replacement therapy reversed the
ovariectomy-induced changes.
Conclusion. Estrogen-dependent COX-2 expression plays an
important role in the RBF regulation in female rats.
Cyclooxygenase (COX) occurs in two isoforms, COX-1
and COX-2, and catalyzes the conversion of arachidonic
Key words: cyclooxygenase-2, ovariectomy, prostaglandins, renal
plasma flow, cells of the thick ascending limb of Henle, estrogen re-
placement therapy.
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acid to prostaglandins, which are known to be important
physiologic modulators of vascular tone and salt and wa-
ter homeostasis in the mammalian kidney [1–3]. COX-1 is
present at relatively stable levels in the kidneys, whereas
COX-2 is constitutively present in the area adjacent to the
macula densa cells of the renal cortex and in medullary
interstitial cells [4, 5].
Previous studies have demonstrated that the COX-2
in the renal cortex contributes to the regulation of renin
synthesis [6] and renal microvascular tone [7], and that
its expression is regulated by dietary salt intake [8, 9],
angiotensin II [10], corticosteroids [11], and furosemide
[12]. However, the effects of ovariectomy on expression
and function of renal COX-2 remain unknown, although a
recent study revealed that the COX-2 promoter gene con-
tains an estrogen-binding site [13]. Therefore, the present
study was performed to determine the effect of ovariec-
tomy and estrogen replacement therapy on renal COX-
2 expression and COX-2–dependent regulation of renal
blood flow.
For headache, arthralgia, and menstrual pain, non-
steroidal anti-inflammatory drugs (NSAIDs) are used
worldwide in hypertensive women [14] who tend to
develop edema and require a salt-restricted diet. Al-
though selective COX-2 inhibitors have been devel-
oped as NSAIDs with few adverse effects, the results
of the present study might suggest caution in clinical
use of COX-2 inhibitors in postmenopausal patients and
post-ovariectomy patients for any reason, especially
when they are on a restricted salt diet.
METHODS
Preparation of animals
Female Sprague-Dawley rats (Charles River Labs,
Wilmington, MA, USA) were housed in wire cages,
and maintained in a temperature-controlled room on a
12:12-hour light-dark cycle. The animals had free access to
water and rat chow consisting of a normal-salt diet (0.4%
NaCl; CE-2; Nihon Clea, Tokyo, Japan) or a low-salt diet
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(0.02%; T-02378; Nihon Clea). All experimental proto-
cols were approved by the Keio University Animal Care
and Use Committee. Rats weighing 175 g to 200 g were
anesthetized with sodium pentobarbital (50 mg/kg, IP),
and ovariectomy or a sham operation was performed via
bilateral flank incisions. The surgically prepared rats were
divided into 4 groups: sham-operated rats fed a normal-
salt diet (Sh+NS), sham-operated rats fed a low-salt diet
(Sh+LS), bilaterally ovariectomized rats fed a normal-
salt diet (Ox+NS), and bilaterally ovariectomized rats
fed a low-salt diet (Ox+LS).
In the estrogen replacement therapy experiments,
pellets containing either 17b-estradiol (0.5 mg per rat
with a 21-day release; Innovative Research of America,
Sarasota, FL, USA) or placebo (0.5 mg per rat with a
21-day release; Innovative Research of America) were
implanted in the subcutaneous tissue of bilaterally
ovariectomized rats. The ovariectomized rats in this series
of experiments were divided into 4 groups: a placebo-
treated group fed a normal-salt diet (Ox+NS+PL); a
placebo-treated group fed a low-salt diet (Ox+LS+PL);
a 17b-estradiol–treated group fed a normal-salt diet
(Ox+NS+ER); and a 17b-estradiol–treated group fed a
low-salt diet (Ox+LS+ER). All experiments were per-
formed on day 14 after surgical preparation. Systolic
blood pressure measured by tail-cuff plethysmography
immediately before the experiments yielded similar val-
ues in all 4 groups, with average values in the Sh+NS,
Sh+LS, Ox+NS, Ox+LS, Ox+NS+PL, Ox+LS+PL,
Ox+NS+ER, and Ox+LS+ER groups of 120 ± 3, 121 ±
2, 119 ± 3, 121 ± 2, 122 ± 2, 123 ± 2, 120 ± 3, and
119 ± 4 mm Hg, respectively (N = 6 in each group).
The plasma estradiol concentration was determined by
radioimmunoassay (RIA), and the values in the sham-
operated rats, ovariectomized rats treated with placebo,
and ovariectomized rats treated with 17b-estradiol were
28.7 ± 4.5, 6.9 ± 1.2, and 78.4 ± 5.2 pg/mL, respectively
(N = 9 in each group).
Determination of the plasma renin activity
One mL of blood was extracted from tail vein on the
day before the clearance study in the ovariectomized and
sham-operated rats fed either low- or normal-salt diet.
The plasma was used to determine plasma renin activ-
ity (PRA) with commercially available RIA kit, accord-
ing to the manufacturer’s instructions (Renin-Riabead,
Dainabot, Tokyo, Japan). PRA was expressed as the rate
of angiotensin I formation (ng/mL/h).
Double-immunolabeling of cyclooxygenase-2 and
Tamm-horsfall glycoprotein
This technique was performed with a modification
of a previously described procedure [15]. Kidney tis-
sue was fixed overnight in 4% phosphate saline-buffered
paraformaldehyde, then rinsed in a series of sucrose
solutions of increasing concentration and snap-frozen.
Dual immunofluorescence (DIF) was performed on 4-lm
cryostat sections. The primary antibodies were as fol-
lows: rabbit polyclonal anti-COX-2 antibody (1:400)
(Cayman Chemical, Ann Arbor, MI, USA) and sheep
polyclonal anti-uromucoid antibody (1:400) (Biodesign
International, Saco, ME, USA), and the secondary an-
tibodies were rhodamin-conjugated anti-rabbit IgG and
fluoroscein isothiocyanate (FITC)-conjugated anti-sheep
IgG (1:500) (Chemicon International, Temecula, CA,
USA). The DIF sections were examined with a confo-
cal microscope (MRC600; BioRad Laboratories, Her-
cules, CA, USA). The secondary antibodies had been
isolated by immunoaffinity chromatography and ab-
sorbed for dual labeling. Control measures included omit-
ting the primary antibody and substituting normal IgG
from the same animal for the primary antibody.
Immunohistochemistry
Kidneys harvested from the rats from each group were
perfused in situ with saline and fixed in Bouin’s solution.
The kidneys were then dehydrated with a graded series of
ethanol and embedded in paraffin. After deparaffiniza-
tion and rehydration, sections (4-lm thick) were boiled
in citrate buffer in a microwave to unmask antigenicity,
immersed in 3% H2O2 in methanol to inhibit endoge-
nous peroxidase, and flooded with 5% bovine serum albu-
min (BSA) in phosphate-buffered saline (PBS) to inhibit
nonspecific reactions. Polyclonal rabbit anti-COX-2 anti-
bodies (160106, 160116, and 160126, Cayman Chemical)
(1:200–500 dilution) were used as the primary antibodies
[16], and a biotinylated polyclonal goat anti-rabbit anti-
body (1:500 dilution) was applied as the secondary anti-
body. Immunoreaction was performed with a Vectastain
ABC-Elite kit (Vector Laboratories, Burlingame, CA,
USA) and visualized with 0.02% 3′,3′-diaminobenzidine
tetrahydrochloride as a substrate followed by light coun-
terstaining with hematoxylin. Control staining was per-
formed with normal rabbit IgG.
Western blotting of renal cortex
The renal cortex or medulla was lysed in T-PERTM
reagent (Pierce, Rockford, IL, USA) containing 25 lL
DTT (1 mol/L) and 250 lL PMSF (100 mmol/L), and after
5-minute centrifugation at 10,000g, the supernatant was
collected and subjected to sodium dodecyl sulfate (SDS)
polyacrylamide gel electrophoresis. The proteins were
transferred to polyvinylidene difluoride membranes, and
after blocking the blots overnight with PBScontaining
5% bovine albumin and 0.5% Tween 20, they were in-
cubated for 16 hours with polyclonal rabbit anti-COX-2
antibody (160116, Cayman Chemical) (1:1000 dilution).
Immunoreactivity was determined by using horseradish
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peroxidase–conjugated donkey anti-rabbit antibody and
the enhanced chemiluminescence reaction, and the
quantitative analyses were performed using Image 1D
(Pharmacia, Peapack, NJ, USA).
Renal clearance study
Renal clearance experiments were performed to assess
the effect of NS398 (Cayman Chemical) on renal hemo-
dynamics and excretory function. Rats were anesthetized
with intraperitoneal pentobarbital sodium (50 mg/
kg), and placed on a thermoregulated surgical table to
maintain rectally monitored body temperature at 37◦C.
A tracheostomy was performed to ensure a patent airway,
and positive-pressure ventilation was maintained with
an artificial respirator (model 7025; Ugo Basile, Com-
erio, Italy) at a rate of 60 strokes/min and a stroke vol-
ume of 10 mL/kg body weight. A PE-60 catheter was
inserted into jugular vein to infuse solutions and pento-
barbital sodium as needed to maintain an appropriate
level of anesthesia. The right femoral artery was can-
nulated, and the cannula was connected to a computer
system (MacLab/8s, AD Instruments, Nagoya, Japan) via
a pressure transducer to monitor arterial pressure. The
right carotid artery was also cannulated to provide sepa-
rate access for intra-arterial bolus doses of NS398.
The left kidney was exposed by a flank incision, iso-
lated from surrounding tissue, and placed in a Lucite
cup to keep it stable. Two needle flow probes (500-lm
diameter) connected to a laser-Doppler flowmeter (Flo-
C1-Twin; Omegawave, Tokyo, Japan) were inserted into
the kidney mass to a depth of 1 mm and 4 mm, respec-
tively, to position their tips in the superficial cortex and
the mid-medullary region, respectively, and measure rel-
ative changes in renal cortical blood flow (CBF) and
medullary blood flow (MBF). The bladder was catheter-
ized with PE-10 tubing via a suprapubic incision for urine
collection. During surgery, isotonic saline solution con-
taining 6% albumin (bovine; Sigma Chemical Co., St.
Louis, MO, USA) was infused at a rate of 20 lL/min.
After surgery, the intravenous infusion was switched to
isotonic saline solution containing 1% albumin, 1.5% p-
aminohippurate sodium (PAH; Merck, Sharp & Dohme,
Hoddesdon, UK), and 7.5% inulin (Inutest; Laevosan,
Linz, Austria), and infused at the same rate. A 90-minute
equilibration period was provided after the completion
of surgery.
The experimental protocol consisted of three
30-minute clearance periods to assess renal function.
The rats were given intra-arterial bolus injections of
increasing doses of NS398 [0, 1, and 10 ng/gram body
weight (gbw)] at 40-minute intervals. NS398 is thought
to selectively inhibit COX-2, and have no effect on
COX-1 activity at the concentrations used in the present
study [17]. After a 10-minute delay, a 30-minute exper-
imental clearance period was provided for each dose
of NS398, and an arterial blood sample was collected
at the midpoint of each 30-minute clearance period to
calculate inulin clearance (Cinulin) and PAH clearance
(CPAH). At the end of each experiment, the left kidney
was removed, stripped of surrounding tissue, blotted
dry, and weighed, so that the data could be normalized
per gram kidney weight (gkw). The microhematocrit of
all arterial blood samples was measured and remained
constant throughout the experiment. Inulin and PAH
concentrations in blood and urine were measured col-
orimetrically, and urinary sodium concentrations were
determined by flame photometry. Cinulin was used as an
index of GFR, and CPAH was used as an index of renal
blood flow (RBF) because of the constant hematocrit
throughout renal clearance study. All drugs were given
in a total volume 100 lL.
Determination of urinary prostaglandin E2 and 6-keto
prostaglandin F1a
The urine samples were collected during the first and
last 30-minute renal clearance periods (i.e., during 30 min-
utes after administration of 0 and 10 ng/gbw of NS398, re-
spectively). The urinary concentration of prostaglandin
(PG) E2 and 6-keto PGF1a were determined by RIA
using a [125I] RIA kit (PerkinElmer Life Sciences, Inc.,
Boston, MA, USA) after the extraction by conventional
methods and subsequent purification on BOND-ELUT
Si columns (Analytichem International, Harbor City, CA,
USA).
Statistical analysis
Statistical comparisons within a group were made by
one-way analysis of variance (ANOVA) for repeated
measures followed by the Newman-Keuls post hoc test.
Differences between two groups were evaluated by two-
way ANOVA for repeated measures combined with the
Newman-Keuls post hoc test. A P value of <0.05 was con-
sidered significant. Data are reported as mean ±SEM.
RESULTS
Double-immunolabeling of COX-2 and Tamm-horsfall
glycoprotein
Figure 1A shows double-immunolabeling with spe-
cific antibodies against COX-2 and Tamm-Horsfall
glycoprotein, and revealed that COX-2 is present in
Tamm-Horsfall–positive cells. Since Tamm-Horsfall gly-
coprotein is a specific antigenic marker of cells in the thick
ascending limb (TAL) of Henle, including macula densa
cells, this finding confirmed that COX-2 was localized ex-
clusively in TAL cells.
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Immunohistochemistry
Figure 1B shows the effects of salt restriction and
ovariectomy on expression of COX-2 in TAL cells. COX-
2 stained weakly in the macula densa cells in the Sh+NS
group, whereas the salt restriction and ovariectomy sim-
ilarly increased the number and intensity of COX-2–
positive macula densa cells in the Sh+LS and Ox+NS
groups. In the Ox+LS group, on the other hand, the num-
ber of COX-2–positive cells increased not only adjacent
to the macula densa, but along the TAL segment as well,
and the intensity of the COX-2 staining was also greater
than in any of the other three groups.
Figure 1C shows the effects of estrogen replacement
therapy on the expression of renal cortical COX-2 in
ovariectomized rats fed either a normal- or low-salt diet.
In either a normal- or low-salt diet, estradiol adminis-
tration decreased the number and intensity of COX-2–
positive cells increased by ovariectomy.
Western blotting of renal cortex and medulla
Figure 2A shows the results of immunoblotting of mi-
crosomes from renal cortex with antiserum specific for
COX-2, and they revealed immunoreactrive protein with
a molecular mass of −73kD in all four groups. The COX-2
immunoblotting increased with salt restriction, ovariec-
tomy, and both (Sh+NS<Ox+NS = Sh+LS<Ox+LS).
Ovariectomy enhanced the COX-2 immunoblotting in
both the rats fed the low- and the normal-salt diet. Com-
bined with the immunohistochemistry findings, these re-
sults suggest that ovariectomy enhances expression of
COX-2 in TAL cells independently of salt intake, al-
though salt restriction significantly enhanced the expres-
sion of COX-2.
Figure 2B shows the results of immunoblotting of mi-
crosomes from renal medulla with antiserum specific for
COX-2, and they revealed immunoreactrive protein with
a molecular mass of −73kD in all four groups. Salt restric-
tion decreased the medullary COX-2 immunoblotting in
sham-operated rats, whereas salt restriction increased
it in ovariectomized rats. Ovariectomy decreased the
medullary COX-2 immunoblotting in rats fed a normal-
salt diet, but increased it in rats fed a low-salt diet.
Figure 2C shows the effects of estrogen replacement
therapy on the COX-2 immunoblotting of microsomes
from renal cortex. Estrogen replacement decreased the
cortical COX-2 immunoblotting in the ovariectmomized
rats fed either a normal- or a low-salt diet. Combined with
the immunohistochemical findings, in ovariectomized
rats, estrogen replacement appears to inhibit the renal
cortical expression of COX-2 independently of dietary
salt. Figure 2D shows the effects of estrogen replacement
therapy on the medullary COX-2 immunoblotting. Salt
restriction increased the medullary COX-2 immunoblot-
ting in ovariectomized rats treated with placebo, whereas
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Fig. 2. Representative Western blotting and quantitative analysis of
COX-2 protein expression. (A) COX-2 protein expression in the renal
cortex of sham-operated rats fed a normal-salt diet (Sh+NS, N = 6),
sham-operated rats fed a low-salt diet (Sh+LS, N = 6), ovariectomized
rats fed a normal-salt diet (Ox+NS, N = 6), and ovariectomized rats fed
a low-salt diet (Ox+LS, N = 6). (B) COX-2 protein expression in the
renal medulla of sham-operated rats fed a normal-salt diet (Sh+NS, N
= 6), sham-operated rats fed a low-salt diet (Sh+LS, N = 6), ovariec-
tomized rats fed a normal-salt diet (Ox+NS, N = 6), and ovariectomized
rats fed a low-salt diet (Ox+LS, N = 6). (C) COX-2 protein expres-
sion in the renal cortex of ovariectomized rats. Placebo-treated rats
fed a normal-salt diet (Ox+NS+PL, N = 6), estradiol-treated rats fed
a normal salt diet (Ox+NS+ER, N = 6), placebo-treated rats fed a
low salt diet (Ox+LS+PL, N = 6), and estradiol-treated rats fed a
low salt diet (Ox+LS+ER, N = 6). (D) COX-2 protein expression in
the renal medulla of ovariectomized rats. Placebo-treated rats fed a
normal-salt diet (Ox+NS+PL, N = 6), estradiol-treated rats fed a nor-
mal salt diet (Ox+NS+ER, N = 6), placebo-treated rats fed a low salt
diet (Ox+LS+PL, N = 6), and estradiol-treated rats fed a low salt diet
(Ox+LS+ER, N = 6). ∗P < 0.05 for Ox vs. Sh; †P < 0.05 for LS vs. NS;
§P < 0.05 for ER vs. PL.
salt restriction decreased it in ovariectomized rats treated
with estrogen. Estrogen replacement therapy increased
the medullary COX-2 immunoblotting in ovariectomized
rats fed a normal-salt diet, but decreased it in rats fed a
low-salt diet.
Plasma renin activity
The average values of PRA in the Sh+NS, Sh+LS,
Ox+NS, and Ox+LS groups were 14.6 ± 1.9, 54.2 ±
9.5, 19.6 ± 3.0, and 63.9 ± 9.6, respectively (N = 4 in
each group). PRA was significantly increased by salt re-
striction both in ovariectomized and sham-operated rats.
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Table 1. Urinary excretion of prostaglandin E2 and 6-keto
prostaglandin F1a before and during NS398 treatment
NS398 treatment Before During
Prostaglandin E2 (ng/h)
Sh+NS (N = 6) 21.8±3.2 4.5 ± 0.7a
Sh+LS (N = 6) 24.6 ± 1.8 5.4 ± 0.6a
Ox+NS (N = 6) 35.2 ± 8.6 6.7 ± 1.1a
Ox+LS (N = 6) 36.8 ± 5.4b 6.2 ± 1.2a
6-keto prostaglandin F1 a (ng/h)
Sh+NS (N = 6) 2.7 ± 0.6 0.8 ± 0.2a
Sh+LS (N = 6) 14.4 ± 1.9b 2.8 ± 0.8a
Ox+NS (N = 6) 16.9 ± 1.9b 2.9 ± 0.7a
Ox+LS (N = 6) 35.8 ± 6.6b,c,d 1.9 ± 0.8a
Sh+NS, sham-operated rats fed a normal-salt diet; Sh+LS, sham-operated
rats fed a low-salt diet; Ox+NS, ovariectomized rats fed a normal-salt diet;
Ox+LS, ovariectomized rats fed a low-salt diet. Data are mean ± SEM.
aP < 0.05 versus before NS398 treatment; bP < 0.05 vs. Sh+NS; cP < 0.05 for
Ox+LS vs. Sh+LS; dP < 0.05 for Ox+LS vs. Ox+NS.
Ovariectomy slightly increased PRA without a signifi-
cance in either the rats fed a normal- or low-salt diet.
This result was consistent with previous studies showing
that postmenopausal women have higher plasma renin
levels than premenopausal women [18].
Urinary prostaglandin excretion
Table 1 shows urinary excretion of PGE2 and 6-keto
PGF1a in the Sh+NS, Sh+LS, Ox+NS, and Ox+LS
groups before and during COX-2 inhibition with NS398.
Urinary excretion of PGE2 was significantly greater
in Ox+LS group than in Sh+NS group. Ovariectomy
tended to increase urinary excretion of PGE2 in rats
fed either the normal- or low-salt diet. The low-salt diet
did not affect urinary excretion of PGE2 in either sham-
operated or ovariectomized rats. Urinary excretion of 6-
keto PGF1a, however, was elevated by ovariectomy or
the low-salt diet, and it was further increased by ovariec-
tomy and the low-salt diet in combination. COX-2 inhi-
bition significantly decreased urinary excretion of PGE2
and 6-keto PGF1a in all four groups.
Renal clearance study
Table 2 shows BP, Cinulin, and UNaV in the Sh+NS,
Sh+LS, Ox+NS, and Ox+LS groups before and during
COX-2 inhibition with NS398. The UNaV values in the
Sh+LS and Ox+LS groups were significantly lower than
in the Sh+NS and Ox+NS groups, but no significant dif-
ferences in the basal values of BP or Cinulin were ob-
served among the four groups. NS398 did not affect BP,
Cinulin, or UNaV significantly in any of the four groups,
although it significantly decreased urinary excretion of
prostaglandins. As shown in Figure 3, however, COX-
2 inhibition with NS398 significantly decreased CPAH
in the Sh+LS, Ox+NS, and Ox+LS groups, but did not
change it in the Sh+NS group, even though the basal
CPAH level in the four groups was similar. Before, and
Table 2. Blood pressure, inulin clearance, and urinary sodium
excretion before and during NS398 treatment in the Sh+NS, Sh+LS,
Ox+NS, and Ox+LS groups
NS398 ng/g of
body weight 0 1 10
Blood pressure mm Hg
Sh+NS (N = 6) 92 ± 7 89 ± 7 89 ± 8
Sh+LS (N = 6) 92 ± 5 89 ± 5 88 ± 6
Ox+NS (N = 6) 95 ± 5 93 ± 4 91 ± 5
Ox+LS (N = 6) 93 ± 4 90 ± 4 87 ± 6
Cinulin mL/min/g of kidney weight
Sh+NS (N = 6) 1.52 ± 0.06 1.43 ± 0.11 1.42 ± 0.15
Sh+LS (N = 6) 1.48 ± 0.13 1.42 ± 0.09 1.42 ± 0.11
Ox+NS (N = 6) 1.48 ± 0.06 1.42 ± 0.10 1.43 ± 0.13
Ox+LS (N = 6) 1.50 ± 0.09 1.42 ± 0.10 1.40 ± 0.12
UNaV mEq/30 min
Sh+NS (N = 6) 0.145 ± 0.006 0.110 ± 0.018 0.118 ± 0.007
Sh+LS (N = 6) 0.057 ± 0.011a 0.055 ± 0.014a 0.045 ± 0.017a
Ox+NS (N = 6) 0.151 ± 0.030 0.128 ± 0.048 0.129 ± 0.065
Ox+LS (N = 6) 0.037 ± 0.005a 0.047 ± 0.011a 0.052 ± 0.011a
Abbreviations are: Cinulin, inulin clearance; UNaV, urinary sodium excretion.
Data are mean ± SEM.
aP < 0.05 for LS vs. NS in the sham-operated or ovariectomized rats.
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Fig. 3. Effect of COX-2 inhibition with NS398 on p-aminohippurate
clearance (CPAH) in sham-operated rats fed a normal-salt diet
(Sh+NS, N = 6), sham-operated rats fed a low-salt diet (Sh+LS,
N = 6), ovariectomized rats fed a normal-salt diet (Ox+NS, N = 6),
and ovariectomized rats fed a low-salt diet (Ox+LS, N = 6). ∗P < 0.05
vs. 0 ng/g body weight (gbw). †P < 0.05 vs. the other groups.
during treatment with the 1 ng/gbw and 10 ng/gbw doses
of NS398, the CPAH values averaged 6.0 ± 0.4, 5.7 ± 0.5,
and 5.7 ± 0.5 mL/min/gkw, respectively, in the Sh+NS
group, 6.1 ± 0.4, 5.5 ± 0.5, and 4.8 ± 0.5 mL/min/gkw,
respectively, in the Sh+LS group, 5.9 ± 0.5, 5.0 ± 0.3,
and 4.5 ± 0.3 mL/min/gkw, respectively, in the Ox+NS
group, and 6.1 ± 0.4, 4.2 ± 0.3, and 3.6 ± 0.2 mL/min/gkw,
respectively, in the Ox+LS group. The magnitude of the
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Fig. 4. Changes in cortical blood flow (CBF) and medullary blood flow (MBF) during COX-2 inhibition with NS398. (A) CBF during COX-2
inhibitor with NS398 in sham-operated rats fed a normal-salt diet (Sh+NS, N = 6), sham-operated rats fed a low-salt diet (Sh+LS, N = 6),
ovariectomized rats fed a normal-salt diet (Ox+NS, N = 6), and ovariectomized rats fed a low-salt diet (Ox+LS, N = 6). (B) MBF during COX-2
inhibition with NS398 in Sh+NS (N = 6), Sh+LS (N = 6), Ox+NS (N = 6), and Ox+LS (N = 6). ∗P < 0.05 vs. 0 ng/g of body weight (gbw).
decrease in CPAH was significantly greater in the Ox+LS
group (2.5 ± 0.4 mL/min/gkw) than in the Sh+LS group
(1.3 ± 0.4 mL/min/gkw, P = 0.0313) and Ox+NS group
(1.4 ± 0.3 mL/min/gkw, P = 0.0478). In the Sh+LS group,
indomethacin (10 ng/gbw) was administered at the con-
clusion of renal clearance study. CPAH was significantly
decreased to 2.6 ± 0.5 mL/min/gkw. This result suggested
that NS398 is selective for COX-2 up to 10 ng/gbw.
Figure 4A shows the changes in CBF during COX-2
inhibition with NS398. In the Sh+NS group, NS398 had
no effect on CBF. In the Sh+LS and Ox+NS groups
however, the 10 ng/gbw doses of NS398 significantly de-
creased CBF by 31.7 ± 7.8% and 27.2 ± 7.2%, respec-
tively, and in the Ox+LS group, it significantly decreased
CBF by 24.2 ± 3.3%. The NS398-induced decrease in
CBF was similar in the Sh+LS, Os+NS, and Ox+LS
groups. Figure 4B shows the changes in MBF during
COX-2 inhibition with NS398. In the Sh+NS and Ox+LS
groups, COX-2 inhibition with 10 ng/gbw NS398 caused
a similar decrease in MBF by 18.3 ± 6.6% and 15.8 ±
3.3%, respectively, whereas NS398 did not affect MBF in
the Sh+LS and Ox+NS groups. All of the reductions in
CBF and MBF induced by the intra-arterial injection of
NS398 had a gentle downward slope with no peak, and
were sustained for a 30-minute experimental clearance
period.
Table 3 shows the BP, Cinulin, and UNaV values
in the Ox+NS+PL, Ox+LS+PL, Ox+NS+ER, and
Ox+LS+ER groups before and during COX-2 inhibition
with NS398. The UNaV values in the PL+LS and ER+LS
groups were significantly lower than in the PL+NS and
Table 3. Blood pressure, inulin clearance, and urinary sodium
excretion before and during NS398 treatment
NS398 ng/g of
body weight 0 1 10
Blood pressure mm Hg
Ox+NS+PL (N = 9) 94 ± 3 93 ± 3 95 ± 4
Ox+LS+PL (N = 9) 95 ± 2 92 ± 3 90 ± 5
Ox+NS+ER (N = 9) 95 ± 3 93 ± 3 93 ± 4
Ox+LS+ER (N = 9) 92 ± 4 90 ± 4 88 ± 4
Cinulin mL/min/g of kidney weight
Ox+NS+PL (N = 9) 1.46 ± 0.04 1.39 ± 0.06 1.31 ± 0.08
Ox+LS+PL (N = 9) 1.40 ± 0.08 1.41 ± 0.10 1.33 ± 0.13
Ox+NS+ER (N = 9) 1.49 ± 0.03 1.46 ± 0.06 1.41 ± 0.08
Ox+LS+ER (N = 9) 1.44 ± 0.09 1.39 ± 0.07 1.34 ± 0.08
UNaV mEq/30 min
Ox+NS+PL (N = 9) 0.194 ± 0.028 0.196 ± 0.037 0.202 ± 0.046
Ox+LS+PL (N = 9) 0.040 ± 0.007a 0.051 ± 0.009a 0.054 ± 0.010a
Ox+NS+ER (N = 9) 0.173 ± 0.008 0.170 ± 0.019 0.154 ± 0.012
Ox+LS+ER (N = 9) 0.051 ± 0.008a 0.052 ± 0.010a 0.047 ± 0.012a
Data are mean ± SEM.
aP < 0.05 for LS vs. NS in the placebo- or 17b-estradiol–treated ovariectomized
rats.
ER+NS groups, but no significant differences between
the basal BP or Cinulin values were observed among the
four groups. NS398 did not significantly affect BP, Cin-
ulin, or UNaV in any of the four groups. As shown in
Figure 5, however, COX-2 inhibition with NS398 signifi-
cantly decreased CPAH in the Ox+LS+PL, Ox+NS+PL,
and Ox+LS+ER groups, but did not change CPAH in the
Ox+NS+ER group. The CPAH value before and dur-
ing treatment with the 1 ng/gbw and 10 ng/gbw doses of
NS398 averaged 5.9 ± 0.3, 4.3 ± 0.3, and 3.7 ± 0.2 mL/
min/gkw, respectively, in the Ox+LS+PL group, 5.8 ±
0.4, 5.1 ± 0.2, and 4.6 ± 0.2 mL/min/gkw, respectively, in
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Fig. 5. Effect of COX-2 inhibition with NS398 on p -aminohippurate
clearance (CPAH) in ovariectomized rats. Placebo-treated rats fed a
normal-salt diet (Ox+NS+PL, N = 9), placebo- treated rats fed a low-
salt diet (Ox+LS+PL, N = 9), 17b-estradiol–treated rats fed a normal-
salt diet (Ox+NS+ER, N = 9), and 17b-estradiol–treated rats fed a
low-salt diet (Ox+LS+ER, N = 9). ∗P < 0.05 vs. 0 ng/g body weight
(gbw). †P < 0.05 vs. the other groups.
the Ox+NS+PL group, 5.5 ± 0.3, 4.9 ± 0.4, and 4.3 ±
0.4 mL/min/gkw, respectively, in the Ox+LS+ER group,
and 5.4 ± 0.3, 5.4 ± 0.4, and 5.3 ± 0.4 mL/min/gkw, re-
spectively, in the Ox+NS+ER group. The magnitude of
the decrease in CPAH was similar in the Ox+LS+ER
group (1.2 ± 0.2 mL/min/gkw) and Ox+NS+PL group
(1.2 ± 0.2 mL/min/gkw), but it was significantly greater
in the Ox+LS+PL group (2.1 ± 0.2 mL/min/gkw) than
in the Ox+LS+ER and Ox+NS+PL groups. NS398 did
not alter CPAH in the Ox+NS+ER group.
Figure 6A shows the changes in CBF during COX-2
inhibition with NS398. In the Ox+LS+PL, Ox+LS+ER,
and Ox+NS+PL groups, 10 ng/gbw NS398 similarly de-
creased CBF by 26.9 ± 3.2%, 22.9 ± 2.3%, and 23.8 ±
4.9%, respectively. In the Ox+NS+ER group, however,
NS398 had no effect on CBF. Figure 6B shows the changes
in MBF during COX-2 inhibition with NS398. In the
Ox+LS+PL group, COX-2 inhibition with 10 ng/gbw
NS398 significantly decreased MBF by 20.0 ± 3.0%,
whereas NS398 did not alter MBF in the Ox+LS+ER,
Ox+NS+PL, or Ox+NS+ER groups.
DISCUSSION
The expression of COX-2 was enhanced in the re-
nal cortical TAL cells of ovariectomized rats compared
with that in sham-operated rats. Because this enhance-
ment was observed when rats were fed either a low- or
normal-salt diet, the ovariectomy appears to have en-
hanced renal cortical COX-2 expression independently
of salt-dependent regulatory mechanisms. In the present
study, ovariectomy increased urinary PGE2 excretion in
rats fed a low-salt diet and increased the urinary excre-
tion of 6-keto-PGF1a, a breakdown product of unsta-
ble PGI2, in rats fed either a low- or normal-salt diet.
The inhibition of COX-2 using NS398 significantly de-
creased the urinary excretion of 6-keto-PGF1a and PGE2.
The reduction in the urinary excretion of 6-keto-PGF1a
was greater in the Ox+LS group than in the Sh+LS or
Ox+NS groups, which in turn had a greater reduction
than the Sh+NS group. These results suggest that the
enhancement of COX-2 expression induced by ovariec-
tomy and low-salt diet stimulates the renal production
of PGI2, a well-known vasodilator in the human kidney,
and of PGE2, which dilates the afferent arterioles via
EP2 receptors, and buffers the renal vasoconstrictor re-
sponses that are mediated by the EP1 and EP3 recep-
tors [19]. In addition, NS398 significantly decreased the
RBF in the Sh+LS, Ox+NS, and Ox+LS groups, in which
renal cortical COX-2 expression was enhanced; the re-
ductions in RBF in these three groups were associated
with decreases in the urinary excretion of 6-keto-PGF1a
and PGE2. Therefore, the increased expression of re-
nal cortical COX-2 in response to salt restriction and
ovariectomy can stimulate the production of vasodilator
prostaglandins and contribute to the regulation of renal
blood flow.
Under normal conditions, most of the RBF perfuses
the renal cortex; thus, the NS398-induced changes in to-
tal RBF may be primarily due to changes in renal CBF.
In contrast, renal MBF accounts for only 10% of the total
RBF [20] when the CBF remains intact, and the reduction
in MBF is a negligible part of the overall RBF. This was
supported by evidence that that NS398 significantly de-
creased renal MBF in the Sh+NS group, but did not affect
the total RBF. However, the reduction in the total RBF
in the Ox+LS group was greater than those observed in
the Ox+NS and Sh+LS groups, and the reduction in the
CBF in these three groups was similar. Because NS398
significantly decreased the MBF in the Ox+LS group,
the decrease in MBF might significantly affect the over-
all RBF in the Ox+LS group. Thus, once the CBF has
been reduced, the contribution of MBF to the overall
RBF can increase significantly.
COX-2 is constitutively expressed in renal medullary
interstitial cells [21, 22]; since previous studies have
demonstrated that salt loading enhances renal medullary
COX-2 expression [23], salt restriction may stimu-
late renal cortical COX-2 expression and inhibit renal
medullary COX-2 expression. The latter hypothesis was
confirmed by the results of the present study, which
showed that salt restriction inhibited renal medullary
COX-2 expression in sham-operated rats. In the Sh+LS
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Fig. 6. Changes in cortical blood flow (CBF) and medullary blood flow (MBF) during COX-2 inhibition with NS398 in ovariectomized rats. (A)
CBF during COX-2 inhibition with NS398 in placebo-treated rats fed a normal-salt diet (Ox+NS+PL, N = 9), placebo-treated rats fed a low-salt
diet (Ox+LS+PL, N = 9), 17b-estradiol–treated rats fed a normal-salt diet (Ox+NS+ER, N = 9), and 17b-estradiol–treated rats fed a low-salt diet
(Ox+LS+ER, N = 9). (B) MBF during COX-2 inhibition with NS398 in Ox+NS+PL (N = 9), Ox+LS+PL (N = 9), Ox+NS+ER (N = 9), and
Ox+LS+ER (N = 9). ∗P < 0.05 vs. 0 ng/g of body weight (gbw).
group, therefore, COX-2 inhibition did not affect the
renal MBF. In addition, ovariectomy reduced renal
medullary COX-2 expression in animals fed a normal-
salt diet, and increases renal medullary COX-2 expres-
sion in animals fed a low-salt diet. Ovariectomy can
reduce COX-2 expression in renal medullary interstitial
cells, whereas ovariectomy combined with salt restric-
tion can increase COX-2 expression of the TAL cells to-
ward the medulla, thereby accounting for the enhance-
ment of renal medullary COX-2 expression in the Ox+LS
group. This hypothesis was supported by the immunohis-
tochemistry findings in the present study, which showed
that COX-2 expression of the TAL cells increased to-
ward the renal medulla in ovariectomized rats. There-
fore, COX-2 inhibition did not affect renal MBF in the
Ox+NS group, but significantly decreased renal MBF in
the Ox+LS group.
Previous studies have shown that an acute injection of
COX-2 inhibitor does not affect the RBF in euvolemic
animals fed a standard diet [24, 25]. These results are
consistent with the results of the present study. Also, in
previous studies, nimesulide, a selective COX-2 inhibitor,
reduced UNaV in animals fed a normal-salt diet, but did
not influence UNaV in animals fed a low-salt diet [26]; in
the present study, NS398 did not affect UNaV in animals
fed either a normal- or a low-salt diet. In these studies,
however, the UNaV of the rats fed normal- and low-salt
diets averaged 30 to 60 lEq/min and 3 lEq/min, respec-
tively. In the present study, the UNaV of the rats fed a
normal-salt diet averaged 5 lEq/min, and was similar to
that of the rats fed a low-salt diet in the previous study
[26]. Therefore, the normal-salt diet in the present study
was closer to the low-salt diet rather than the normal-salt
diet in the previous study [26], and NS398 did not influ-
ence the UNaV of the rats fed a normal-salt diet in the
present study.
COX-2 inhibition elicited an elevation in the filtration
fraction, with a decrease in RBF, but no change in GFR,
in the Sh+LS, Ox+NS, and Ox+LS groups. These re-
sults suggest that the enhancement of COX-2 may influ-
ence not only the afferent but also the efferent arterioles.
However, previous studies have demonstrated that mac-
ula densa COX-2 predominantly influences the afferent
arterioles during enhanced tubuloglomerular feedback
activity [7]; thus, ovariectomy may alter the efferent arte-
riolar response. Further studies are needed to clarify the
effects of COX-2 on renal microcirculation in ovariec-
tomized rats.
Several studies have demonstrated the cell-specific reg-
ulation of COX-2 expression by estrogen. Estrogen up-
regulates COX-2 expression in endothelial cells of human
umbilical vein [27], the uterine stroma and epithelium
of the guinea pig [28], the endometrium of the rat [29],
and the endometrium [30, 31] and myometrium of ovine
[30], but down-regulates it in the chondrocytes [32] and
epithelial cells [33] of bovines. In the present study, es-
trogen replacement decreased the enhanced COX-2 ex-
pression and improved the COX-2–dependent regulation
of RBF in the kidneys of ovariectomized rats. Because
this decrease was observed when rats were fed either a
low- or normal-salt diet, estrogen replacement appears to
inhibit renal cortical COX-2 expression independently of
salt diet.
Although the mechanism of renal COX-2 regulation
by estrogen has not been clearly defined, several pos-
sible mechanisms have been proposed. A recent study
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revealed that the COX-2 promoter gene contains an
estrogen-binding site [13], suggesting that estrogen may
directly affect expression of the COX-2. Previous stud-
ies demonstrated that estrogen up-regulates the expres-
sion of endothelial nitric oxide synthesis (eNOS) and
neuronal nitric oxide synthesis (nNOS), but down-
regulates expression of inducible nitric oxide synthe-
sis (iNOS) [34, 35]. Since nNOS-derived NO stimulates
COX-2 activity in the kidneys [7], estrogen may influ-
ence renal COX-2 expression through stimulation of the
NO systems. Moreover, a recent study showed that es-
trogen up-regulates renal Ang II type 2 receptors [36],
and since Ang II type 1 receptors inhibit renal COX-2
expression [37], the Ang II type 2 receptors enhanced
by estrogen may antagonize the inhibitory effect of Ang
II type 1 receptors on renal COX-2 expression. A pre-
vious work has shown that estradiol stimulates adrenal
activity [38–40], and since adrenalectomy enhances re-
nal COX-2 expression, and the enhancement is reversed
by replacement therapy with either corticosterone or
deoxycorticosterone [41], estrogen may also enhance
renal COX-2 expression by stimulating glucocorticoid
receptor-mediated function. Thus, NO, Ang II, or glu-
cocorticoid hormones may significantly contribute to the
mechanism of up-regulation of renal COX-2 by ovariec-
tomy, but further study is required to clarify the mecha-
nisms.
CONCLUSION
Ovariectomy enhances the expression of COX-2 ad-
jacent to the macula densa and along the TAL segment
through a mechanism that is independent of salt intake.
This enhancement was reversed by estrogen replacement
therapy. Therefore, estrogen-dependent COX-2 expres-
sion plays an important role in the regulation of renal
blood flow in female rats.
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